I have always thought that throwing a random assortment of companies into an "Others" category is the laziest trick in finance. This hodgepodge of Hong Kong stocks—spanning medical imaging, precision manufacturing, natural gas, and media—looks exactly like an island of misfit toys. But here is the truth: even in this forgotten corner, you can see the brutal reality of the 2026 market. You are either adapting to the new tech cycle, or you are fast asleep.

This is wild, and here's why. In a year where AI is restructuring every value chain, even traditional foundries are scrambling to get a piece of the pie. Look at Impro Precision (1286.HK). They reported a stellar H1 revenue of HKD 3.02 billion, up 23.2% year-over-year. Analysts at Daiwa and Everbright are cheering for their high-horsepower engines and the new Mexican facility, which directly tap into the cooling and infrastructure needs of US AI data centers. This is how you pivot, and their recent outperformance against the sector is completely justified.

In stark contrast, Ju Teng International (3336.HK) is a train wreck. The legacy notebook casing manufacturer issued a massive profit warning in July, projecting a net loss between HKD 750 million and HKD 850 million for the first half of the year. Right now, they are just sitting around waiting for Lens Technology's acquisition to clear antitrust reviews. Good luck with that. Until the deal closes, it is nothing but a very expensive waiting game.

The intersection of healthcare and AI is a great pitch, but the execution is always messier. Easy Health (2661.HK) is trying to ride the AI wave sparked by MINIMAX for a valuation rebound. But with global AI medical regulations tightening, compliance is a massive hurdle. Show me the actual revenue, not just the buzzwords. In the same healthcare space, Rimag Group (2522.HK) is doing much more solid work with its medical imaging cloud platform. Their impressive year-to-date gains prove that real infrastructure always wins over hype.

Then we have the boring, defensive plays. China Gas (0384.HK) just issued 750 million RMB in medium-term notes and comfortably sits on the Fortune China 500 list. Transforming into an integrated energy provider? It sounds incredibly tedious, but in a volatile market, boring is exactly what risk-averse capital is looking for.

Why aren't the rest moving faster? The remainder of this list is basically populated by ghosts. Most Kwai Chung (1716.HK) is drifting through a volatile advertising market, while AV Concept Holdings (0595.HK) has short-term assets covering liabilities but absolutely zero growth narrative. As for the graphite electrodes of Sanergy Group (2459.HK), and the painfully quiet OnCure (1489.HK) and Yi Mei International (83690.HK)—if you cannot make a single wave in the grand narrative of 2026, do not act surprised when the market prices you at zero. If you are not at the table, you are on the menu.

This article does not constitute investment advice.